 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 11 | 1/1 | 返回列表 |
| 查看: 284 | 回復: 10 | |||
[交流]
Introduction要這么寫，又快又好！深容Introduction智能體實測
|
|||
|
如需試用【深容SCI寫作智能體】，請微信聯(lián)系深容張老師：shenrongagent [https://scioriginal.com] SCI論文的Introduction部分，并不涉及自已的研究內(nèi)容，而是通過對現(xiàn)有知識體系的批判性分析，引出自已研究的必要性。 通過分析大量的論文，我們發(fā)現(xiàn)中國作者寫的Introduction篇幅一般都很短，好像三言兩語就可以說明白了，但很難引人入勝：你可以說是言簡意賅，也可以說是語言貧瘠。 下面我們看看如何利用【深容SCI寫作智能體】更快、更好地寫作Introduction。 您只需要輸入論文標題，關鍵詞，所涉及的內(nèi)容提示詞，智能體就可以從數(shù)據(jù)庫中檢索最新相關文獻，然后高效起草Introduction。如下： 恭喜您！Introduction 起草成功了，讓我們看看智能體的寫作質量吧： ■ Introduction 1. Breast Cancer: A Prevalent and Complex Disease Breast cancer stands as one of the most prevalent malignancies among women worldwide, with a significant impact on public health and quality of life. According to global cancer statistics, breast cancer accounts for a substantial proportion of new cancer cases and cancer - related deaths each year [9]. Its high incidence rate underscores the urgent need for a comprehensive understanding of its underlying mechanisms and the development of effective therapeutic strategies. Breast cancer is a heterogeneous disease, characterized by diverse molecular subtypes that exhibit distinct biological behaviors, clinical features, and treatment responses. These subtypes are primarily classified based on the expression of hormone receptors, such as estrogen receptor (ER) and progesterone receptor (PR), as well as the human epidermal growth factor receptor 2 (HER2). Hormone - receptor - positive breast cancers, which express either ER or PR or both, constitute the majority of cases. These tumors are often driven by hormonal signaling pathways and are typically treated with endocrine therapies that target the estrogen signaling axis, such as tamoxifen and aromatase inhibitors [9]. HER2 - positive breast cancers, on the other hand, overexpress the HER2 protein and are associated with a more aggressive clinical course. Targeted therapies against HER2, such as trastuzumab, have significantly improved the prognosis of patients with this subtype [9]. Triple - negative breast cancer (TNBC), which lacks expression of ER, PR, and HER2, is known for its high aggressiveness and limited treatment options, often relying on chemotherapy as the mainstay of treatment [9]. 2. The Role of Cyclin - Dependent Kinases in Breast Cancer Cyclin - dependent kinases (CDKs) are a family of serine/threonine kinases that play crucial roles in regulating the cell cycle progression. In the context of breast cancer, dysregulation of CDK activity is a common feature and contributes to uncontrolled cell proliferation, a hallmark of cancer. CDK4 and CDK6, in particular, are key regulators of the G1 - S phase transition of the cell cycle. They form complexes with cyclin D and phosphorylate the retinoblastoma protein (Rb), leading to the release of transcription factors such as E2F, which then activate genes required for DNA synthesis and cell cycle progression [8]. In hormone - receptor - positive breast cancer, the cyclin D - CDK4/6 - Rb pathway is often hyperactivated. Cyclin D1 is an estrogen - responsive gene, and its overexpression is frequently observed in ER - positive breast tumors. This hyperactivation of the CDK4/6 pathway promotes cell cycle progression and tumor growth, making it an attractive therapeutic target [6]. As a result, CDK4/6 inhibitors have emerged as a new class of targeted therapies for hormone - receptor - positive breast cancer. 3. Ribociclib: A CDK4/6 Inhibitor in Breast Cancer Treatment Ribociclib is a selective oral CDK4/6 inhibitor that has shown promising results in the treatment of hormone - receptor - positive, HER2 - negative advanced breast cancer. By inhibiting CDK4/6 activity, ribociclib blocks the phosphorylation of Rb, thereby preventing the release of E2F and arresting the cell cycle in the G1 phase. This leads to inhibition of tumor cell proliferation and growth [6]. Clinical trials have demonstrated that the combination of ribociclib with endocrine therapies, such as letrozole or fulvestrant, significantly improves progression - free survival (PFS) compared to endocrine therapy alone in patients with advanced hormone - receptor - positive breast cancer [17]. These results have led to the approval of ribociclib by regulatory agencies for the treatment of this patient population, providing a new and effective treatment option. However, despite the initial success of ribociclib, the development of resistance remains a major challenge in the long - term management of breast cancer patients. Understanding the mechanisms underlying ribociclib resistance is crucial for the development of strategies to overcome it and improve patient outcomes. 4. The LAP2 - Emerin - MAN1 (LEM) Domain Family and LEM4 The LAP2 - Emerin - MAN1 (LEM) domain family is a group of inner nuclear membrane proteins that play important roles in nuclear structure, chromatin organization, and gene regulation. These proteins share a conserved LEM domain, which mediates their interaction with chromatin - associated proteins such as Barrier - to - Autointegration Factor (BAF) [3]. LEM4, also known as NET29, is a member of the LEM domain family. It is located at the inner nuclear membrane and has been implicated in various cellular processes, including cell cycle regulation, DNA damage response, and gene expression modulation [3]. Previous studies have shown that LEM4 can interact with several proteins involved in cell cycle control, such as CDK1 and cyclin B1, and regulate their activity. This suggests that LEM4 may play a role in cell cycle progression and tumor development [3]. In the context of breast cancer, the expression and function of LEM4 have not been extensively studied. However, emerging evidence suggests that LEM4 may be involved in the regulation of signaling pathways that are relevant to breast cancer progression and treatment resistance. For example, some studies have indicated that LEM4 can interact with components of the Wnt\/beta - catenin signaling pathway, which is known to be dysregulated in various cancers, including breast cancer [8]. 5. The Wnt/beta - Catenin Signaling Pathway and Its Role in Breast Cancer The Wnt\/beta - catenin signaling pathway is a highly conserved signaling cascade that plays critical roles in embryonic development, tissue homeostasis, and cancer. In the absence of Wnt ligands, beta - catenin is sequestered in a cytoplasmic complex consisting of axin, adenomatous polyposis coli (APC), glycogen synthase kinase - 3beta (GSK - 3beta), and casein kinase 1 (CK1). This complex promotes the phosphorylation and ubiquitination of beta - catenin, leading to its proteasomal degradation [3]. When Wnt ligands bind to their cell surface receptors, Frizzled and low - density lipoprotein receptor - related protein 5\/6 (LRP5\/6), the cytoplasmic complex is disrupted, and beta - catenin is stabilized. Stabilized beta - catenin then translocates into the nucleus, where it forms a complex with transcription factors such as T - cell factor/lymphoid enhancer factor (TCF\/LEF) and activates the transcription of target genes involved in cell proliferation, survival, and differentiation [6]. In breast cancer, dysregulation of the Wnt\/beta - catenin signaling pathway has been frequently observed. Aberrant activation of this pathway can contribute to tumor initiation, progression, and metastasis. For example, overexpression of Wnt ligands, mutations in components of the degradation complex (such as APC or beta - catenin itself), or activation of downstream signaling molecules can lead to constitutive activation of beta - catenin - dependent transcription and promote breast cancer development [8]. Moreover, the Wnt/beta - catenin pathway has been implicated in the regulation of cancer stem cells, which are thought to be responsible for tumor recurrence and treatment resistance [8]. 6. The Potential Link between LEM4, beta - Catenin, and Ribociclib Resistance Given the roles of LEM4 in cell cycle regulation and its potential interaction with the Wnt/beta - catenin signaling pathway, as well as the importance of the Wnt/beta - catenin pathway in breast cancer and treatment resistance, it is reasonable to hypothesize that LEM4 may be involved in the development of ribociclib resistance in breast cancer cells through its interaction with beta - catenin. Previous studies have shown that the Wnt\/beta - catenin pathway can cross - talk with other signaling pathways involved in cell cycle regulation, such as the CDK4/6 - Rb pathway. For example, beta - catenin can directly or indirectly regulate the expression of cyclin D1, a key component of the CDK4/6 - Rb pathway [8]. This suggests that activation of the Wnt\/beta - catenin pathway may bypass the inhibitory effects of CDK4/6 inhibitors, leading to the development of resistance. If LEM4 can promote beta - catenin - dependent transcription activity, it may enhance the expression of genes involved in cell cycle progression and survival, thereby counteracting the cell cycle arrest induced by ribociclib. This would provide a mechanism for breast cancer cells to escape the growth - inhibitory effects of ribociclib and develop resistance. Therefore, the LEM4/beta - catenin axis represents a potential therapeutic strategy to overcome ribociclib resistance in breast cancer cells. Breast cancer is a complex and heterogeneous disease with diverse molecular subtypes. The CDK4\/6 inhibitor ribociclib has shown significant efficacy in the treatment of hormone - receptor - positive breast cancer, but the development of resistance remains a major challenge. LEM4, a member of the LEM domain family, has the potential to interact with the Wnt/beta - catenin signaling pathway, which is dysregulated in breast cancer and implicated in treatment resistance. Understanding the role of the LEM4/beta - catenin axis in ribociclib resistance may provide new insights into the mechanisms of resistance and lead to the development of novel therapeutic strategies to overcome it, ultimately improving the prognosis of breast cancer patients. References [3] Nasiri Kenari F, Saberian M, Abikenari M, Najafi S, Sadeghizadeh M Restoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance. BioMed Research International. 2025. 2025. 5824748. PMID: 41031251. DOI: 10.1155/bmri/5824748. 篇幅原因，省略其它參考文獻...... 以上這篇Introduction起草時間僅00:02:53 如需試用【深容SCI寫作智能體】，請微信聯(lián)系深容張老師：shenrongagent [https://scioriginal.com] #SCI論文 #科研 #實驗 #博士 #投稿 更多推薦： [Method智能體]：3分鐘起草SCI論文Method，并引用真實參考文獻？ |
回復此樓» 猜你喜歡
中國林科院林化所（南京）2026年招收化學/材料/環(huán)境工程等背景碩士研究生3名
已經(jīng)有3人回復
-
306求調劑
已經(jīng)有7人回復
-
0703化學 學碩 理工科均可 不區(qū)分研究方向 總分279求調劑
已經(jīng)有4人回復
-
0856材料工程，初試313調劑
已經(jīng)有7人回復
-
化工專碩調劑
已經(jīng)有7人回復
-
085600 英一數(shù)二272求調劑
已經(jīng)有44人回復
-
歡迎采礦、地質、巖土、計算機、人工智能等專業(yè)的同學報考
已經(jīng)有10人回復
-
298求調劑一志愿中海洋
已經(jīng)有3人回復
-
環(huán)境調劑
已經(jīng)有7人回復
-
0703化學306調劑
已經(jīng)有4人回復
» 搶金幣啦！回帖就可以得到:
-
江西師大化學工程學院2026招收化學化工相關調劑生110+人
+2/878
-
江西師范大學陶端健教授團隊2026年碩士研究生招生公告
+1/232
-
Alicat多功能流量控制的氣體混配技術- 艾里卡特 (Alicat)
+2/96
-
湖南大學材料科學與工程學院招收博士研究生
+1/35
-
哈爾濱工業(yè)大學博士招生
+1/33
-
河南大學張琳教授團隊招收博士研究生
+1/26
-
華中科技大學牛廣達教授招聘博士后
+1/18
-
26屆計算機、電子信息類、電科、控制、通信考研T j信息pp駿：74+08+76+6+20
+1/11
-
中山大學-先進制造學院-智能驅動方向-招收2026年9月入學博士生
+1/10
-
26申博 l 醫(yī)學背景 l 生信碩士
+1/9
-
深圳大學何傳新課題組誠聘博士后、（副）研究員
+1/7
-
香港科技大學 招生 2026 Fall全獎博士 -- 機械/電子/材料
+1/6
-
中國科學院國家級人才團隊博士后招聘啟示
+1/5
-
2026南京林業(yè)大學化學工程學院招收化學/材料研究背景申請考核博士生1名
+1/4
-
食品考研交流
+1/4
-
澳洲皇家墨爾本理工RMIT招收【AI隱私安全， 隱私計算方向】 CSC訪問學者 聯(lián)合培養(yǎng)
+1/4
-
大灣區(qū)大學姚瑤課題組2026屆博士生招生
+1/4
-
接受藥學調劑
+1/2
-
山西師范大學 材料科學與工程學院招收碩士調劑生
+1/2
-
12408 計算機307求調劑
+1/1
簡單回復
yuekong2樓
2026-01-03 16:44
回復
2026-01-03 16:47
回復
2026-01-03 16:48
回復
XG-WUST5樓
2026-01-03 17:15
回復
pheiphei2025(金幣+1): 謝謝參與
up 發(fā)自小木蟲IOS客戶端
s9659z6樓
2026-01-03 20:18
回復
pheiphei2025(金幣+1): 謝謝參與
庚辰辛丑7樓
2026-01-03 20:36
回復
pheiphei2025(金幣+1): 謝謝參與
2026-01-03 21:02
回復
pheiphei2025(金幣+1): 謝謝參與
傾城染憶9樓
2026-01-03 22:25
回復
pheiphei2025(金幣+1): 謝謝參與
。 發(fā)自小木蟲IOS客戶端
psylhh10樓
2026-01-03 23:44
回復
pheiphei2025(金幣+1): 謝謝參與
我才是肖牧沖11樓
2026-01-04 08:58
回復
pheiphei2025(金幣+1): 謝謝參與
。 發(fā)自小木蟲手機客戶端
相關版塊跳轉
我要訂閱樓主 pheiphei2025 的主題更新
| 11 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 0856材料工程，初試313調劑 +7 | 賣個關子吧 2026-03-03 | 7/350 |
|
|---|---|---|---|---|
|
[考研]
085600 英一數(shù)二272求調劑
5+6
|
vida_a 2026-03-01 | 44/2200 |
|
|
|
[考研] 298求調劑一志愿中海洋 +3 | lour. 2026-03-03 | 3/150 |
|
|
|
[考研] 0703化學306調劑 +4 | 26要上岸 2026-03-03 | 4/200 |
|
|
|
[考研] 一志愿東北大學化學314分求調劑 +5 | lr1212.. 2026-03-02 | 5/250 |
|
|
|
[考研] 268求調劑 +10 | 簡單點0 2026-03-02 | 14/700 |
|
|
|
[考研] 278求調劑 +3 | 滿天星11_22 2026-03-02 | 3/150 |
|
|
|
[考研] 080500材料科學與工程 +4 | 202114020319 2026-03-03 | 4/200 |
|
|
|
[考研] 295求調劑。一志愿報考鄭州大學化學工藝學碩，總分295分 +8 | yl1 2026-03-02 | 9/450 |
|
|
|
[考研] 085600求調劑 +4 | LRZZZZZZ 2026-03-02 | 5/250 |
|
|
|
[考研] 材料085601調劑 +5 | 多多子. 2026-03-02 | 5/250 |
|
|
|
[考研] 一志愿華南理工大學材料與化工326分，求調劑 +3 | wujinrui1 2026-02-28 | 3/150 |
|
|
|
[考研] 哈工大計算機劉劼團隊招生 +4 | hit_aiot 2026-03-01 | 6/300 |
|
|
|
[考研] 化工專碩342，一志愿大連理工大學，求調劑 +6 | kyf化工 2026-02-28 | 7/350 |
|
|
|
[考研] 材料調劑 +6 | 愛擦汗的可樂冰 2026-02-28 | 7/350 |
|
|
|
[考博] 26申博 +4 | 想申博！ 2026-02-26 | 6/300 |
|
|
|
[考研] 328求調劑 +3 | aaadim 2026-03-01 | 5/250 |
|
|
|
[考研] 304求調劑 +6 | 曼殊2266 2026-02-28 | 7/350 |
|
|
|
[考研] 295復試調劑 +3 | 簡木ChuFront 2026-03-01 | 3/150 |
|
|
|
[考研] 311求調劑 +9 | 南迦720 2026-02-28 | 10/500 |
|